Treatment Resistant Cancers
Resistivity
Resistance
Therapeutic Index
Equivalent Resistance
Resistance and Conductance
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Feb 13, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
Cameron A Wade1, Natasha Kyprianou2,3,4
1Departments of Urology, University of Kentucky College of Medicine, Lexington, Kentucky, KY 40536, USA. cameron.wade@uky.edu.
Therapeutic resistance in advanced prostate cancer is driven by the tumor microenvironment and epithelial-mesenchymal transition (EMT). Targeting EMT-MET dynamics offers a new strategy to overcome treatment resistance in metastatic castration-resistant prostate cancer (mCRPC).
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: